Volastra

Developer of an artificial intelligence-enabled platform designed to advance synthetic lethal oncology. The company's platform identifies novel synthetic lethal targets and biomarkers and develops small-molecule therapeutic drug candidates, enabling clients to discover and develop treatments for cancer.

Provider of drug discovery and development services intended to redefine care for women and men through purpose-driven science. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Developer of a cloud-based software intended to bring vital drugs, vaccines, and medical devices to market. The company's platform helps to move beyond digital promotional reviews by providing actionable insights that inspire more effective collateral and smarter marketing decisions all with a reduced cost and risk, enabling life science companies to get timely analytics to optimize essential processes.